Valeant » Products & Pipeline » Neurology

By: Valeant  09-12-2011
Keywords: neurology, Product Portfolio, Pharmaceutical Company

Neurology and Other

Our comprehensive portfolio of well-established specialty pharmaceuticals targets neurological diseases such as epilepsy, migraines, depression, chronic pain, Huntington's disease, Parkinson's disease and orphan diseases. Valeant's Neurology and Other product portfolio offers hope for relief to patients suffering from these conditions.

Valeant's key neurology products are Wellbutrin® XL, a once-daily formulation of bupropion for the treatment of depression and seasonal affective disorder; Cesamet®, an oral antiemetic for chemotherapy-induced nausea; Diastat®, a benzodiazepine anticonvulsant; Nitoman® (tetrabenazine) for the treatment of hyperkinetic movement disorders, including chorea associated with Huntington's disease, and Xyrem®, a central nervous system (CNS) depressant. In the field of pain management, key products are Onsolis, a fentanyl citrate buccal soluble film for the treatment of breakthrough cancer pain, and Ralivia®, a once-daily formulation of tramadol for the treatment of chronic pain.

In May 2010, Valeant acquired Aton Pharma, Inc., a specialty pharmaceutical company focused on ophthalmology and certain orphan drug indications, located in Lawrenceville, New Jersey. This acquisition significantly enhances Valeant's neurology and other products franchise in the United States with both an in-line business and a development pipeline consisting primarily of orphan drug compounds. The acquisition of Aton fits into Valeant's long-term strategy to pursue diversified opportunities within the pharmaceutical market and offers another platform for future growth.

Keywords: neurology, Pharmaceutical Company, Pharmaceutical Market, Product Portfolio

Other products and services from Valeant

09-12-2011

Valeant » Products & Pipeline » Consumer Brands » Dermatix™ Ultra

Hissyfit products offer multiple benefits that include the highest level of environmental protection, anti-ageing properties and cosmetic enhancement for face, body, lip and hands. With beautiful fragrances, gorgeous colors and advanced botanical extracts, our products are for smart women who want to enhance and protect their beauty for flawless results.


09-12-2011

Valeant » Products & Pipeline » Consumer Brands » Kinerase

Kinerase® is a gentle, yet effective skin care regimen scientifically shown to improve the appearance of skin aging, sun damage, blotchiness and roughness. The power behind Kinerase® is kinetin – a plant-based extract that helps visibly improve the appearance of aging and sun-damaged skin. The Pro+ Therapy difference is zeatin – a next generation plant-based extract derived from plant RNA that is proprietary to Valeant.


09-12-2011

Valeant » Products & Pipeline

Our promising early and late-stage drug candidates have unique formulations and mechanisms of action including ezogabine/retigabine for pain treatment and several dermatology candidates for the treatment of rosacea, acne, and dermatological fungus. With major products in the areas of dermatology and neurology, branded generics, and consumer and cosmeceutical products, Valeant is at the forefront of tomorrow's caring and therapeutic challenges.


09-12-2011

Valeant » Products & Pipeline » Dermatology

We also acquired a state-of-the-art manufacturing plant that has the capacity to support our future growth strategies and will allow us to close our current subscale manufacturing facility, while reducing our dependency on third party manufacturers.


09-12-2011

Valeant » Products & Pipeline » Consumer Brands

In 2009, Valeant acquired Private Formula International Holdings Pty Limited, a leading skincare company in Australia and New Zealand and obtained global rights to Dr. LeWinn's Private Formula®, a premium skincare line, Hissyfit®, an anti-aging skincare line, and Revitanail®, a line of nail strengtheners.